Immunity in response to particulate antigen-delivery systems
- PMID: 15560945
- DOI: 10.1016/j.addr.2004.09.008
Immunity in response to particulate antigen-delivery systems
Abstract
Adjuvants and antigen-delivery systems are essential in inducing and modifying immune responses, and despite the variety of materials available for such use, mechanisms by which they support immunity appear to be little known. A common denominator for most antigen-delivery systems is their particulate nature. Together with a certain depot effect, it is the particulate nature that primarily decides whether the antigen-delivery system will be successful in inducing an immune response. If this first requirement is fulfilled, the chemical composition of the vaccine decides which type of immune response will develop, e.g. which isotype of antibodies the B cells will produce, and which cytokines the T cells will secrete, and can be controlled by combining the antigen with immunomodulatory or co-stimulatory molecules. It is our goal to provide an overview of the cellular and molecular factors involved in the induction of immunity and how such factors may influence the potency of an adjuvant or a vaccine. Such factors should then be implemented in the design of new vaccines or in tuning the properties of existing vaccines in order to reach the properties that are necessary for successful vaccination.
Similar articles
-
New generation of mucosal adjuvants for the induction of protective immunity.Rev Med Virol. 2003 Sep-Oct;13(5):293-310. doi: 10.1002/rmv.398. Rev Med Virol. 2003. PMID: 12931340 Review.
-
Mucosal delivery of vaccine antigens and its advantages in pediatrics.Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. doi: 10.1016/j.addr.2006.01.002. Epub 2006 Mar 3. Adv Drug Deliv Rev. 2006. PMID: 16516335 Review.
-
Induction and direction of immune responses by vaccine adjuvants.Crit Rev Immunol. 2001;21(1-3):75-85. Crit Rev Immunol. 2001. PMID: 11642615 Review.
-
Biomaterials as vaccine adjuvants.Biotechnol Prog. 2008 Jul-Aug;24(4):807-14. doi: 10.1002/btpr.10. Biotechnol Prog. 2008. PMID: 19194892 Review.
-
Particulate delivery systems for vaccines: what can we expect?J Pharm Pharmacol. 2006 Jun;58(6):717-28. doi: 10.1211/jpp.58.6.0002. J Pharm Pharmacol. 2006. PMID: 16734973 Review.
Cited by
-
Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.Mol Pharm. 2015 May 4;12(5):1356-65. doi: 10.1021/mp500589c. Epub 2015 Apr 8. Mol Pharm. 2015. PMID: 25817072 Free PMC article.
-
Precision Nanovaccines for Potent Vaccination.JACS Au. 2024 Jul 31;4(8):2792-2810. doi: 10.1021/jacsau.4c00568. eCollection 2024 Aug 26. JACS Au. 2024. PMID: 39211600 Free PMC article. Review.
-
Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores.NPJ Vaccines. 2020 Jul 10;5:59. doi: 10.1038/s41541-020-0208-3. eCollection 2020. NPJ Vaccines. 2020. PMID: 32685200 Free PMC article.
-
Induction of boosted immune response in mice by leptospiral surface proteins expressed in fusion with DnaK.Biomed Res Int. 2014;2014:564285. doi: 10.1155/2014/564285. Epub 2014 Jul 6. Biomed Res Int. 2014. PMID: 25110682 Free PMC article.
-
Enhancing vaccine effectiveness with delivery technology.Curr Opin Biotechnol. 2016 Dec;42:24-29. doi: 10.1016/j.copbio.2016.02.022. Epub 2016 Mar 6. Curr Opin Biotechnol. 2016. PMID: 26954947 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical